Hybrid system fails to show results Shimadzu Medical Systems is finding the going tough in the U.S.MRI market. The vendor is scaling back its direct-sales MRI effortin favor of a distributor and dealer sales network. Shimadzu said last month
Shimadzu Medical Systems is finding the going tough in the U.S.MRI market. The vendor is scaling back its direct-sales MRI effortin favor of a distributor and dealer sales network.
Shimadzu said last month that sales emphasis in MRI would beshifted to the existing authorized distributor and dealer network.The move was made in reaction to slow sales in the MRI segment,which has dropped more than 50% in the last two years, accordingto Mark Silverman, Shimadzu's MRI director.
"This is a response to declining reimbursement economics,health-care reform and the shrinkage of the private MRI market,"Silverman said. "Shimadzu is committed to increasing itsworldwide MRI presence and will continue to offer MRI in the U.S."
Shimadzu has long relied on dealers and distributors for MRIsales. The vendor last year implemented a hybrid direct/distributor/dealersystem in a move to bring more of the sales effort in-house asShimadzu geared up its drive for U.S. market share (SCAN 7/28/93).That system apparently failed to pay off, however.
In conjunction with the change in MRI sale emphasis, Shimadzuhas streamlined its corporate staff, the Torrance, CA, companysaid. Shimadzu will maintain its MRI R&D effort in Japan.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.